A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects
A Phase I, Open Label, Single Dose Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects
Sponsor: Sumitomo Pharma America, Inc.
This PHASE1 trial investigates ADME and Healthy and is currently completed. Sumitomo Pharma America, Inc. leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Completed PHASE1
-
May 2022 — Nov 2023 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jan 2021 — May 2022 [monthly]
Completed PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Oct 2018 — Aug 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sumitomo Pharma America, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .